Stakeholders want to replace the traditional preclinical path with a non-linear process that incorporates new technologies, patient-relevant tests and systems pharmacology.
Thomas Jefferson University has a new approach to fostering innovation and attracting industry partnerships that it hopes will energize biotech in Philadelphia.
Novogen has a first-in-class actin inhibitor that spares normal cells by targeting a cancer-specific tropomyosin.
Janssen is hoping to gain an early read on autoimmune diseases before symptoms appear by developing methods to track changes in a patient's repertoire of T cell receptors.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.